Business · 31/08/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ONGLYZA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of ONGLYZA, a human drug product, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →